NCT06411002View on ClinicalTrials.gov

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

December 12, 2024

Study Completion Date

February 12, 2025

Conditions
Glabellar Frown Lines
Interventions
DRUG

DAXXIFY

Intramuscular injection of daxibotulintoxinA-lanm

Trial Locations (1)

37203

Revance, Nashville

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT06411002 - Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines | Biotech Hunter | Biotech Hunter